The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of October 6, 2025 in Altimmune, Inc. Lawsuit - ALT

Core Viewpoint - Altimmune, Inc. faced significant stock price decline following the announcement of disappointing results from its IMPACT Phase 2b MASH trial for Pemvidutide, leading to allegations of inflated expectations by the company [1]. Group 1: Company Performance - On June 26, 2025, Altimmune announced topline results from the IMPACT Phase 2b MASH trial, which failed to achieve statistical significance in the primary endpoint of fibrosis reduction [1]. - The stock price of Altimmune dropped from $7.71 per share on June 25, 2025, to $3.61 per share on June 26, 2025, marking a decline of 53.2% in one day [1]. Group 2: Legal Actions - Shareholders who purchased shares of ALT between August 10, 2023, and June 25, 2025, are encouraged to contact the Gross Law Firm regarding potential lead plaintiff appointments in a class action lawsuit [1][2]. - The deadline for shareholders to register for the class action and seek lead plaintiff status is October 6, 2025 [2]. Group 3: Firm's Mission - The Gross Law Firm aims to protect the rights of investors affected by deceit, fraud, and illegal business practices, ensuring companies adhere to responsible business practices [3].